Session Details

Morning Session 1 – MSC therapy; Rationalism vs. Empiricism; How much must we know to test therapies in patients; A Live Debate
Friday, September 13, 2019 07:30 AM - 08:30 AM
Ballroom A
This will be the first ever live debate for ISCT. The debate will center around the question – “How much data do we really need before we treat patients?”. The Rationalists support the idea that it is our ethical duty to understand as much as possible the safety and efficacy of an experimental therapy in substantiated animal models (or the like) before testing these therapies in humans. The empiricist approach will argue that it is our ethical duty to rapidly integrate these novel therapies into treatment and that it is acceptable to tolerate risk to patients to do so. There will be no fisticuffs at this debate and there will be an audience voted winner.


Allan Dietz, PhD, Mayo Clinic, USA


MSC - Is in vivo persistence the key to potency? A rational approach for pragmatic trials
Jacques Galipeau, MD, University of Wisconsin - Madison, USA
Learning objectives:
•      Appreciate emerging pre-clinical mouse data informing a persistence hypothesis for potency
•      Appreciate the rational pharmacological use of MSC in human studies
•      The fundamental emerging role of patient selection predicated on predictive biomarkers of MSC response

Application of cell therapies to human disease
William Faubion, MD, Mayo Clinic, USA
Learning objectives:
•      Understand the path to regulatory approval of cell therapies in human disease
•      Understand application of cell therapy in IBD
•      Understand the landscape of pharmacologic therapy for IBD